Nevertheless, preclinical studies demonstrated the anti-obesity effect of OXM since a chronic administration leads to superior weight loss and comparable glucose lowering to a GLP1R-selective peptide [93,94]. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.